P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)ECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Lichtenstein, G.(2);Nakase, H.(3);Armuzzi, A.(4);Kucharzik, T.(5);Levy, G.(6);Palac, H.(6);Kujawski, M.(6);Klaff, J.(6);Cheon, J.H.(7);
(1)University of Calgary Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada;(2)University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, United States;(3)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(4)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(5)Klinikum Lüneburg, Division of Gastroenterology and Hepatology, Lüneburg, Germany;(6)AbbVie Inc, Immunology, North Chicago, United States;(7)Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;
P520: Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programmeECCO’23 CopenhagenYear: 2023
Authors: van der Woude, J.(1)*;Schreiber , S.(2);Peyrin-Biroulet , L.(3);Szekanecz, Z.(4);Choy, E.H.(5);Stiers, P.J.(6);Van Hoek, P.(7);Van Beneden, K.(8);de Haas, A.(9);Rudolph , C.(10);ten Cate, H.(11);
(1)Erasmus Medical Center Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)University Hospital Schleswig-Holstein, Department Medicine I, Kiel, Germany;(3)University Hospital of Nancy, Division of Gastroenterology, Vandoeuvre-lès-Nancy, France;(4)University of Debrecen, Department of Rheumatology- Faculty of Medicine, Debrecen, Hungary;(5)Cardiff University School of Medicine, CREATE Centre- Section of Rheumatology- Division of Infection and Immunity, Cardiff, United Kingdom;(6)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(7)Galapagos NV, Clinical Development Department, Mechelen, Belgium;(8)Galapagos NV, Medical Affairs Department, Mechelen, Belgium;(9)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(10)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(11)Maastricht University Medical Centre, Department of Internal Medicine, Maastricht, The Netherlands;
P521: Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitisECCO’23 CopenhagenYear: 2023
Authors: Outtier, A.(1)*;Louis, E.(2);Dewit, O.(3);Schops, G.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
(1)UZ Leuven, Gastroenterology, Leuven, Belgium;(2)CHU Liège, Gastroenterology, Liège, Belgium;(3)Cliniques Universitaires Saint-Luc, Gastroenterology, Bruxelles, Belgium;
P522: Kono-S anastomosis reduces endoscopic and surgical post-operative recurrence in Crohn's disease. The SuPREMe-CD Trial Update.ECCO’23 CopenhagenYear: 2023
Authors: Luglio, G.(1)*;Rispo, A.(2);Tropeano, F.P.(3);Giglio, M.C.(4);Cricrì, M.(4);Imperatore, N.(5);De Sire, R.(4);Guarino, A.D.(4);Bucci, L.(6);Castiglione, F.(4);De Palma, G.D.(4);
(1)University of Naples Federico II, Department of Public Health - Surgical Endoscopy Unit, Napoli, Italy;(2)University of Naples Federico II, Department of Clinical Medicine and Surgery - Gastroenterology Unit, Naples, Italy;(3)University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, Italy;(4)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(5)Ospedale Santa Maria delle Grazie Pozzuoli, Department of Medicine, Pozzuoli, Italy;(6)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;
P523: Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn's Colitis Care (CCCare): A real world observational study.ECCO’23 CopenhagenYear: 2023
Authors: Cheema, M.(1)*;Narouz, I.(2);Pipicella, J.(3);Garden , F.(4);Lynch, K.(5);Andrews, J.(5);Ghaly, S.(2);Connor, S.(1);
(1)Liverpool Hospital, Department of Gastroenterology and Hepatology, Liverpool, Australia;(2)St. Vincent's hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(3)University of New South Wales, Medicine SWS Clinical School, Liverpool, Australia;(4)University of New South Wales, School of Clinical Medicine- South Western Sydney Clinical Campus, Liverpool, Australia;(5)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;
P524: Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC studyECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.(1);Ben-Horin, S.(2);Ye, B.D.(3);Kim, D.H.(4);Reinisch, W.(5)*;
(1)University Hospital Schleswig-Holstein, Department for Internal Medicine I, Kiel, Germany;(2)Tel Aviv University, Gastroenterology Department- Chaim Sheba Medical Center, Tel-Hashomer, Israel;(3)University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center- Asan Medical Center, Seoul, Korea- Republic Of;(4)Celltrion Healthcare Co., Ltd, Incheon, Korea- Republic Of;(5)Medical University of Vienna, Department of Internal Medicine III- Division of Gastroenterology and Hepatology, Vienna, Austria;
P525: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Taxonera, C.(1)*;Olivares, D.(1);Olga N, L.G.(2);Alba, C.(1);
(1)Hospital Clínico San Carlos, IBD Unit- Department of Gastroenterology, Madrid, Spain;(2)Hospital Clínico San Carlos, Department of Gastroenterology, Madrid, Spain;
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialECCO’23 CopenhagenYear: 2023
Authors: Van Linschoten, R.(1,2)*;Jansen, F.(3);Pauwels, R.(2);Smits, L.(3);Atsma, F.(4);Kievit, W.(5);de Jong, D.(3);de Vries, A.(2);Boekema, P.(6);West, R.(1);Bodelier, A.(7);Gisbertz, I.(8);Wolfhagen, F.(9);Romkens, T.(10);Lutgens, M.(11);van Bodegraven, A.(12);Oldenburg, B.(13);Pierik, M.(14);Russel, M.(15);de Boer, N.(16);Mallant-Hent, R.(17);ter Borg, P.(18);van der Meulen-de Jong, A.(19);Jansen, J.(20);Jansen, S.(21);Tan, A.(22);van der Woude, C.J.(2);Hoentjen, F.(23);
(1)Franciscus Gasthuis & Vlietland, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus MC, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;(3)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(4)Radboud University Medical Center, IQ Healthcare, Nijmegen, The Netherlands;(5)Radboud University Medical Center, Radboud institute for Health Science- Department for Health Evidence, Nijmegen, The Netherlands;(6)Maxima Medical Center, Department of Gastroenterology and Hepatology, Eindhoven, The Netherlands;(7)Amphia Hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands;(8)Bernhoven Hospital, Department of Gastroenterology and Hepatology, Uden, The Netherlands;(9)Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, The Netherlands;(10)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(11)Elisabeth Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(12)Zuyderland Medical Center, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen/Heerlen, The Netherlands;(13)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(14)Maastricht University Medical Center+, Department of Gastroenterology and Hepatology, Maasstricht, The Netherlands;(15)Medisch Spectrum Twente, Department of Gastroenterology and Hepatology, Twente, The Netherlands;(16)Amsterdam University Medical Center- Vrije University Amsterdam, Department of Gastroenterology and Hepatology- AGEM research institute, Amsterdam, The Netherlands;(17)Flevoziekenhuis, Department of Gastroenterology and Hepatology, Almere, The Netherlands;(18)Ikazia Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(19)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(20)OLVG, Department of Gastroenterology and Hepatology, Roterdam, The Netherlands;(21)Reinier de Graaf Gasthuis, Department of Gastroenterology and Hepatology, Delft, The Netherlands;(22)Canisius Wilhelmina Hospital, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(23)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;on behalf of the LADI study group and the Dutch Initiative on Crohn and Colitis (ICC)
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
(1)Kagoshima University Graduate School of Medical and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima city, Japan;
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Kadleckova, B.(1);
(1)Nemocnica Bory - Penta Hospitals, Department of Gastroenterology, Bratislava, Slovakia;(2)Nemocnica Bory - Penta Hospitals, Department of Surgery, Bratislava, Slovakia;
P529: Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life settingECCO’23 CopenhagenYear: 2023
Authors: Laharie, D.(1)*;Pierron, G.(2);Brault, Y.(3);Bouhnik, Y.(4);Nancey, S.(5);
(1)University Hospital Center of Bordeaux, Department of Gastroenterology, Bordeaux, France;(2)Pfizer, Inflammation and Immunology, Paris, France;(3)Pfizer, Statistics, Paris, France;(4)Groupe hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(5)Lyon South Hospital- Pierre-Bénite- and INSERM U1111-CIRI, Department of Gastroenterology, Lyon, France;
P531: A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseasesECCO’23 CopenhagenYear: 2023
Authors: Kantasiripitak, W.(1);WIcha, S.G.(2);Thomas, D.(1);Hoffman , I.(3);Ferrante , M.(4,5);Vermeire , S.(4,5);van Hoeve , K.(3);Dreesen, E.(1,6)*;
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University of Hamburg, Department of Clinical Pharmacy, Hamburg, Germany;(3)University Hospitals Leuven, Department of Paediatric Gastroenterology- Hepatology- and Nutrition, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(6)University of California, Department of Bioengineering and Therapeutic Sciences, Leuven, Belgium;
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance TherapyECCO’23 CopenhagenYear: 2023
Authors: Song, J.H.(1);Hong, S.N.(2)*;Kim, E.R.(3);Kim, J.E.(3);Chang, D.K.(3);Kim, Y.H.(3);
(1)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine- - Seoul- Korea, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(3)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine, Seoul, Korea- Republic Of;
P533: Relation between TL1A expression in intestinal mucosa, and endoscopic severity and clinical course in ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Shimodaira, Y.(1)*;Yoshida, T.(1);Watanabe, K.(1);Takahashi, S.(1);Fukuda, S.(1);Koizumi, S.(1);Matsuhashi, T.(1);Iijima, K.(1);
(1)Akita University Graduate School of Medicine, Department of Gastroenterology and Neurology, Akita City, Japan;
P534: Dual biologic or small molecules therapy in refractory paediatric inflammatory bowel disease (DOUBLE-PIBD): A multi-center study from the paediatric IBD Porto group of ESPGHANECCO’23 CopenhagenYear: 2023
Authors: Cohen, S.(1);Olbjorn, C.(2);Kolho, K.L.(3); Aloi, M.(4);Musto, F.(4);de-Carpi, J.M.(5);Lozano-Ruf, A.(5);Yogev, D.(6);Matar, M.(7);Scarallo, L.(8); Bramuzzo, M.(9); de Ridder, L.(10); Kang, B.(11);Norden, C.(12);Wilson, D.C.(13);Tzivinikos, C.(14); Turner, D.(6);Yerushalmy-Feler, A.(1)*;
(1)Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(2)Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway;(3)Children's Hospital and University of Helsinki- and Tampere University, Department of Paediatric Gastroenterology, Helsinki, Finland;(4)Umberto I Hospital- Sapienza University of Rome, Department of Maternal and Child Health- Pediatric Gastroenterology and Liver Unit, Rome, Italy;(5)Hospital Sant Joan de Déu, Department of Pediatric Gastroenterology- Hepatology and Nutrition, Barcelona, Spain;(6)Shaare Zedek Medical Center- the Hebrew University of Jerusalem, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(7)Schneider Children's Medical Center and the Sackler Faculty of Medicine- Tel Aviv University, Institute of Gastroenterology- Nutrition and Liver Diseases, Tel Aviv, Israel;(8)Meyer Children's Hospital- 50139, Gastroenterology and Nutrition Unit, Florence, Italy;(9)Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", Gastroenterology- Digestive Endoscopy and Nutrition Unit, Trieste, Italy;(10)Erasmus Medical Center/Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands;(11)School of Medicine- Kyungpook National University- 130 Dongdeok-ro- Jung-gu, Department of Pediatrics, Daegu 41944, Korea- Republic Of;(12)Copenhagen University Hospital, The Paediatric Department, Hvidovre, Denmark;(13)Royal Hospital for Sick Children, Department of Paediatric Gastroenterology and Nutrition, Edinburgh, United Kingdom;(14)Al Jalila Children's Specialty Hospital, Pediatric Gastroenterology, Dubai, United Arab Emirates;
P535: COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapyECCO’23 CopenhagenYear: 2023
Authors: Liu, Z.(1)*;Alexander, J.(1);Le, K.(1);Zhou, X.(1);Ibraheim, H.(1);Anandabaskaran, S.(1);Saifuddin, A.(1);Lin, K.(2);Mcfarlane, L.(2);Anand, N.(1);Constable, L.(1);Castro-Seoane, R.(1);Nice, R.(3);Bewshea, C.(3);D'Mello, A.(4);Jones, G.R.(5);Balarajah, S.(1);Fiorentino, F.(6);Sebastian, S.(7);Irving, P.(8);Hicks, L.(1);Williams, H.(1);Kent, A.(9);Linger, R.(10);Parkes, M.(11);Kok, K.(12);Patel, K.V.(13);Teare, J.(14);Altmann, D.(15);Hart, A.(16);Lees, C.(5);Boyton, R.(15);Goodhand, J.(3);Kennedy, N.(3);Pollock, K.(2);Ahmad, T.(3);Powell, N.(1);
(1)Imperial College London, Metabolism- Digestion & Reproduction, London, United Kingdom;(2)Imperial College London, Infectious Diseases, London, United Kingdom;(3)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(4)Imperial College Healthcare NHS Trust, Medicine & Integrated Care, London, United Kingdom;(5)University of Edinburgh, Centre for Inflammation Research, Edinburgh, United Kingdom;(6)King's College London, Nightingale-Saunders Clinical Trials & Epidemiology Unit King's Clinical Trials Unit, London, United Kingdom;(7)Hull University Teaching Hospitals NHS Trust, Gastroenterology, Hull, United Kingdom;(8)King's College London, School of Immunology & Microbial Sciences, London, United Kingdom;(9)King's College Hospital, Gastroenterology, London, United Kingdom;(10)University of Cambridge, The NIHR Bioresource, Cambridge, United Kingdom;(11)University of Cambridge, Gastroenterology, Cambridge, United Kingdom;(12)Bart's Health NHS Trust, Gastroenterology, London, United Kingdom;(13)St George's Hospital NHS Trust, Gastroenterology, London, United Kingdom;(14)Imperial College London, Surgery & Cancer, London, United Kingdom;(15)Imperial College London, Immunology and Inflammation, London, United Kingdom;(16)St Mark's Academic Institute, Gastroenterology, London, United Kingdom;VIP investigators
P536: Is there any association between fat body mass and bone mineral density in patients with Inflammatory Bowel Disease?ECCO’23 CopenhagenYear: 2023
Authors: Ratajczak, A.E.(1)*;Michalak, M.(2);Szymczak-Tomczak, A.(1);Rychter, A.M.(1);Zawada, A.(1);Skoracka, K.(1);Dobrowolska, A.(1);Krela-Kaźmierczak, I.(1);
(1)Poznan University of Medical Sciences, Department of Gastroenterology- Dietetics and Internal Diseases, Poznan, Poland;(2)Poznan University of Medical Sciences, Department of Computer Science and Statistics, Poznan, Poland;
P537: Prevalence of post-COVID-19 vaccination IBD flare-ups: a single-center prospective study.ECCO’23 CopenhagenYear: 2023
Authors: Roblin, X.(1)*;Williet, N.(2);Faure, J.(3);Bastide, L.(2);Barrau, M.(2);Paul, S.(4);
(1)CHU Saint Etienne - Hospital Nord, Department of Gastroenterology and Hepatology- Inserm- CIC1408, Saint Priest en Jarez, France;(2)CHU saint etienne, Gastroenterology, Saint etienne, France;(3)CHU Saint etienne, Gastroenterology, Saint etienne, France;(4)CHU Saint Etienne, Immunology, Saint Etiennne, France;
